First clinical implementation of Yttrium-90 Disc Brachytherapy after FDA clearance.

Purpose: Herein, we study if high-dose-rate (HDR) yttrium-90 (Y) brachytherapy could be utilized by medical physicists, radiation oncologists, and ophthalmic surgeons.

Methods And Materials: Yttrium-90 (Y) beta-emitting brachytherapy sources received United States Food and Drug Administration clearance for episcleral treatment of ocular tumors and benign growths. Dose calibration traceable to the National Institute of Standards and Technology as well as treatment planning and target delineation methods were established.

Early anti-VEGF treatment for radiation maculopathy and optic neuropathy: lessons learned.

Radiation therapy has saved both sight and life for eye cancer patients. The most common methods include ophthalmic plaque brachytherapy and external beam techniques. However, subsequent dose-dependent radiation vasculopathy invariably occurs within and around the targeted zone.

Patients presenting with metastases: stage IV uveal melanoma, an international study.

Objective: To analyse ocular and systemic findings of patients presenting with systemic metastasis.

Methods And Analysis: It is an international, multicentre, internet-enabled, registry-based retrospective data analysis. Patients were diagnosed between 2001 and 2011.

Hypochlorous acid antiseptic washout improves patient comfort after intravitreal injection: A patient reported outcomes study.

Purpose: Current ocular antiseptic practice for intravitreal injection (IVI) employs 5% povidone-iodine (Betadine) drops which frequently cause ocular discomfort and prolonged irritation. In an effort to improve comfort while maintaining efficacy, we studied a hypochlorous acid (HOCL 0.01%) spray washout prior to injection.

Palladium-103 plaque therapy for multifocal iris melanoma: Radiation of the entire anterior segment of the eye.

Purpose: To investigate the safety and tolerability of total anterior segment palladium-103 (Pd) eye plaque brachytherapy for multifocal iris melanoma.

Methods: Interventional case series of 11 patients with multifocal iris melanomas. Anterior segment ultrasound revealed tumor size, location, and intraocular margins.

Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study.

Purpose: To report long-term experience with intravitreal anti-vascular endothelial growth factor treatment for radiation maculopathy.

Methods: From 2005-2015, 120 consecutive patients underwent intravitreal anti-VEGF therapy for radiation maculopathy. Inclusion criteria included a diagnosis of uveal melanoma treated with plaque radiotherapy and subsequent macular radiation vasculopathy (exudate, retinal hemorrhage, intraretinal microangiopathy, neovascularization, edema).

High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.

Purpose: To evaluate the safety and tolerability and treatment efficacy of high-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy.

Methods: A phase I to II open-label, nonrandomized prospective clinical trial was performed on 10 eyes of 10 patients with recalcitrant radiation retinopathy who were failing standard dose anti-vascular endothelial growth factor (VEGF) therapy.

Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study.

Purpose: To test the safety, tolerability, and efficacy of subconjunctival ranibizumab (Lucentis [Genentech, Inc.]) for squamous cell carcinoma of the conjunctiva and cornea.

Methods: Five patients with recurrent squamous cell carcinoma of the conjunctiva and cornea enrolled in this nonrandomized, single center, phase I pilot study as an alternative to radiation or exenteration.

A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve.

Objective: To evaluate slotted eye plaque radiation therapy for choroidal melanomas near the optic disc.

Design: A clinical case series.

Participants: Twenty-four consecutive patients with uveal melanomas that were near, touching, or surrounding the optic disc.

Initial PET/CT staging for choroidal melanoma: AJCC correlation and second nonocular primaries in 333 patients.

Purpose: To report on whole body positron emission tomography/computed tomography (PET/CT) screening for metastasis at diagnosis of primary uveal melanoma.

Methods: Since August 2003, 333 consecutive patients were diagnosed with uveal melanoma and underwent whole body screening for metastatic disease with PET/CT along with liver function tests and physical examination. Abnormal findings prompted further biopsies, blood tests, imaging, or clinical evaluations for confirmation.

Subfoveal choroidal melanoma: pretreatment characteristics and response to plaque radiation therapy.

Objective: To evaluate the clinical presentation, tumor characteristics, and response to palladium 103 plaque radiation therapy for subfoveal choroidal melanomas.

Methods: Retrospective case series of 50 patients diagnosed as having subfoveal melanoma and treated with plaque brachytherapy. Patients underwent evaluation for tumor characteristics, visual acuity, radiation damage, local tumor control, and metastatic disease.

Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma.

Purpose: To evaluate the safety and effect of systemic anti-vascular endothelial growth factor bevacizumab (Avastin) in treatment of exudative retinal detachment secondary to choroidal melanoma.

Methods: Two patients were definitively treated with ophthalmic plaque radiation therapy and subsequently given 10 mg/kg intravenous bevacizumab every 2 weeks for 3 or 4 cycles.

Results: Complete resolution of the exudative retinal detachments occurred 1.

Transpupillary Nd:YAG laser cystotomy for iris pigment epithelial cysts with secondary progressive angle closure.

Two patients were diagnosed as having unilateral iris pigment epithelial (IPE) cysts that were documented to enlarge and induce angle closure. Transpupillary IPE cystotomies were performed using the Nd:YAG laser as a prophylactic measure to prevent angle-closure glaucoma. Anterior chamber anatomy and cyst dimensions were assessed before, during, and after long-term follow-up using slit-lamp biomicroscopy, gonioscopy, and 20- or 35-MHz high-frequency ultrasound imaging.

Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy.

Purpose: To evaluate the intravitreal antivascular endothelial growth factor, bevacizumab, for treatment of radiation optic neuropathy (RON).

Methods And Materials: A prospective interventional clinical case series was performed of 14 patients with RON related to plaque radiotherapy for choroidal melanoma. The RON was characterized by optic disc edema, hemorrhages, microangiopathy, and neovascularization.

Ocular manifestations of multiple myeloma: three cases and a review of the literature.

Background: Multiple myeloma is the most common plasma cell tumor; however, ocular plasmacytomas are rare and can appear in almost any structure of the eye. We present 3 cases, including 2 with unique ophthalmic ultrasound images of ocular plasmacytoma.

Case Reports: Three patients with ocular manifestations of multiple myeloma are described.

Optical coherence tomography/scanning laser ophthalmoscopy imaging of optic nerve head drusen.

Background And Objective: To evaluate optical coherence tomography/scanning laser ophthalmoscopy (OCT/SLO) imaging for optic nerve head drusen (ONHD).

Patients And Methods: Nine consecutive eyes with ONHD were imaged. Each underwent visual field testing, 20-MHz B-scan ultrasonography, photography, and OCT/SLO imaging of the nerve head.

Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy.

Purpose: To examine how tumor characteristics and dose affect cataract development after plaque radiation therapy.

Methods And Materials: Three hundred and eighty-four patients were diagnosed with uveal melanoma and treated with palladium-103 ((103)Pd) plaque radiation therapy. Of these, 282 (74%) inclusion met exclusion criteria for follow-up time, tumor location, and phakic status.

Choroidal metastases fundus autofluorescence imaging: correlation to clinical, OCT, and fluorescein angiographic findings.

Background And Objective: To correlate fundus autofluorescence (FAF) characteristics of metastatic choroidal tumors with optical coherence tomography/scanning laser ophthalmoscope (OCT/SLO).

Patients And Methods: A retrospective review of 10 choroidal metastases in 9 patients.

Results: All tumors were amelanotic, although 8 exhibited surface pigmentation.

[(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy.

Purpose: To evaluate changes in [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) standardized uptake values (SUV) in uveal melanoma before and after plaque brachytherapy.

Methods And Materials: A cohort of 217 patients diagnosed with uveal melanoma and eligible for ophthalmic plaque brachytherapy underwent preoperative PET/CT to evaluate their intraocular tumor and screen for metastasis. Subsequent to undergoing plaque brachytherapy, patients' PET/CT SUV were periodically reevaluated over 42 months.

Fundus Autofluorescence Imaging of Diffuse Uveal Melanocytic Proliferation.

Fundus autofluorescence imaging (FAF) in a case of diffuse uveal melanocytic proliferation is described in this study. It is a rare chorioretinopathy associated with systemic cancer, for which the exact pathological mechanisms are poorly understood. FAF-imaging revealed a diffuse background of hyper-autofluorescence associated with diffuse orange pigment deposition and islands of persistent hypo-fluorescence corresponding to loss of retinal pigment epithelium (RPE).

Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma.

Purpose: To determine how tumor characteristics and radiation dose affect the incidence of radiation maculopathy (RM).

Design: Retrospective, consecutive case series.

Methods: A consecutive case series of 384 uveal melanomas irradiated (mean apical dose, 71.